Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Wisconsin Physicians Services
MINNEAPOLIS, May 30, 2013 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that effective June 1, 2013, Wisconsin Physicians Services (WPS) will begin coverage for Posterior Tibial Nerve Stimulation (PTNS) for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
WPS, a Medicare Administrative Contractor, provides medical and drug benefits to approximately 8.7 million Medicare beneficiaries in the States of Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska and Wisconsin.
“We welcome the WPS decision to provide PTNS coverage for Medicare beneficiaries within its jurisdiction,” said Nancy Kolb, Vice President of Global Marketing. “Beginning June 1, physicians treating Medicare beneficiaries for OAB in the States served by WPS will be reimbursed for PTNS treatments using Uroplasty’s Urgent(®) PC Neuromodulation System.”
The policy will be available on June 1, 2013 on the WPS website at http://www.wpsmedicare.com/.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent(®) PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique(®), an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.
For Further Information: Uroplasty, Inc. EVC Group --------------- --------- Medi Jiwani, Vice President, CFO, Jenifer Kirtland (Investors) and Treasurer 415.568.9349 952.426.6140 Amy Phillips (Media) 412.327.9499
SOURCE Uroplasty, Inc.